ResMed (RMD) shares are pushing higher on Tuesday after a senior RBC Capital Markets analyst upgraded the medical equipment specialist to an “Outperform” rating. In his research note, Craig Wong-Pan cited RMD’s robust Q4 performance as he lifted his price target as well to $262, indicating potential upside of nearly 10% from here.
Note that ResMed stock has already been in a massive uptrend in recent months, currently trading about 28% above its June low.